Chronic Total Occlusion Intervention: Symptom Benefit, Procedural Risk and the Absence of a Prognostic Signal

Abstract

Percutaneous coronary intervention for chronic total occlusions (CTO) delivers a clear symptom benefit: in the EuroCTO
trial, 81.8% of PCI-treated patients reached minimal or no angina (CCS class <2) at 12 months versus 65.7% with optimal
medical therapy alone, and a pooled analysis of EUROCTO and DECISION-CTO found PCI produced clinically meaningful
improvement, exceeding standard thresholds, on every domain of the Seattle Angina Questionnaire. That benefit comes with a
real and quantifiable procedural cost: CTO PCI succeeds less often than other complex PCI (74% versus 98% in one registry
comparison) and carries higher rates of coronary perforation (3.5% versus 2.0%) and cardiac tamponade (0.8% versus
0.1%), with an overall periprocedural complication rate of 9.7% in a large US registry. What CTO PCI has not shown, across
the EuroCTO trial, a pooled meta-analysis, and a separate registry comparison, is any significant difference in hard long-term
outcomes -- cardiovascular death, myocardial infarction, or target lesion failure -- from medical therapy or from other
complex PCI, with every relevant comparison clustering tightly around no difference. This review sets out all three findings
together: a real symptomatic benefit, a real procedural risk, and the absence, so far, of any prognostic signal that would make
this a mortality-reducing intervention rather than a quality-of-life one.